Quanome Technologies (QNME) investor relations material

Company overview and business model

• Operates in pharmaceutical distribution in China, focusing on infusion products, specialty pharmaceuticals, and foods for special medical purposes, serving hospitals and healthcare providers.

• Recently initiated quantum-related technology and AI compute capacity businesses, both in early development with no revenue as of the filing date.

• Disposed of its U.S. logistics business in February 2026 to focus on pharmaceutical and technology initiatives.

• All subsidiaries are wholly owned, with no variable interest entities; main operations are through Hupan Pharmaceutical in the PRC.

• Exploring expansion into digital assets and AI infrastructure, but no concrete operational plans or revenue from these segments yet.

Financial performance and metrics

• As of October 1, 2026, public float was approximately $29.26 million, with 34,427,559 shares held by non-affiliates.

• No dividends have been paid or declared; $12.7 million in aggregate funding provided to PRC subsidiaries to support operations.

• Revenue from pharmaceutical distribution recognized from over 55 customers in the past three fiscal quarters, with five customers accounting for over 10% each.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used as set forth in the applicable prospectus supplement.

• Funding to PRC subsidiaries is subject to PRC regulatory requirements; future funding may require additional registrations or approvals.